Biocryst Pharmaceuticals (BCRX) Cash from Operations Growth (1y) (2011 - 2026)
Biocryst Pharmaceuticals (BCRX) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn | 81.06% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 8.26% |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | -46.22% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 63.59% |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 73.78% |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 33.73% |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | 16.88% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.47 Bn | 2.12 Bn | 214.41 Mn | 152.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 152.63% |
| Mar 31, 2026 | -124.56% |
| Dec 31, 2025 | 5,700.61% |
| Sep 30, 2025 | 404.84% |
| Jun 30, 2025 | 3,119.15% |
| Mar 31, 2025 | 48.74% |
| Dec 31, 2024 | 41.55% |
| Sep 30, 2024 | 141.44% |
| Jun 30, 2024 | 92.73% |
| Mar 31, 2024 | -12.99% |
| Dec 31, 2023 | 62.61% |
| Sep 30, 2023 | 38.67% |
| Jun 30, 2023 | 32.22% |
| Mar 31, 2023 | 38.93% |
| Dec 31, 2022 | 26.53% |
| Sep 30, 2022 | -39.39% |
| Jun 30, 2022 | -9.23% |
| Mar 31, 2022 | -27.52% |
| Dec 31, 2021 | 23.68% |
| Sep 30, 2021 | 39.16% |